LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics' First Quarter 2026 Financial Results Conference Call.
Lenz Therapeutics Inc. (LENZ)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 4,178,823 | $23,735,715 | 0.21% | |
| 2. | Falcon Edge Capital Richard Gerson And Navroz D. Udwadia | 3,612,211 | $20,517,358 | 0.33% | |
| 3. | Squarepoint Ops LLC Maxime Fortin (Cio) | 1,747,096 | $9,923,505 | +16% | 0.01% |
| 4. | Millennium Management Israel Englander | 1,508,478 | $8,568,155 | +74% | 0% |
| 5. | 72 Investment Holdings Steve Cohen | 1,017,751 | $5,780,826 | 11.57% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.92 | 5,592 | $49,890.15 | 5,592 | 2026-03-27 | Filing | |
| $8.95 | 28,089 | $251,410.59 | 77,289 | 2026-03-27 | Filing | |
| $8.57 | 7,500 | $64,275.00 | 12,886 | 2026-03-27 | Filing | |
| $22.79 | 10,500 | $239,278.20 | 10,500 | 2025-11-07 | Filing | |
| $22.76 | 2,178 | $49,562.79 | 5,386 | 2025-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.37 | 5,788 | $152,611.62 | 4,733 | 2025-11-17 | Filing | |
| $25.74 | 4,212 | $108,410.56 | 10,521 | 2025-11-17 | Filing | |
| $47.01 | 123 | $5,782.64 | 764,127 | 2025-09-30 | Filing | |
| $47.01 | 177 | $8,321.35 | 1,050,599 | 2025-09-30 | Filing | |
| $46.41 | 57,502 | $2,668,483.81 | 764,250 | 2025-09-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,558,905 | $20,214,577 | 0% | |
| 2. | 2,656,888 | $15,091,124 | 9.28% | |
| 3. | 2,292,121 | $13,019,246 | 0% | |
| 4. | 1,547,883 | $8,791,975 | 0.01% | |
| 5. | 1,097,755 | $6,235,248 | 0% |
News See All
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q4 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year-end 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutic Third Quarter 2025 Financial Results Conference Call.
Jim Cramer’s Recent Takes on These 12 Stocks
“I'm talking about the extreme dichotomy between focusing on a body of wisened economists who are being pushed around by a president who wants to run the central bank and focusing on the free ruling...
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics First Quarter 2025 Financial Results Conference Call. At this time all participants are in a listen-only mode.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q4 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year End 2024 Financial Results Conference Call. This time all participants are in a listen-only mode.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q3 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics Second Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to LENZ Therapeutics First Quarter 2024 Financial Results and Business Update.
Hedge Fund Resource Center